ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Dr. Tamar Safra on the Usage of PARP Inhibitors in Gynecological Cancers

Tamar Safra, MD
Published Online:2:42 PM, Mon November 30, 2015


Tamar Safra, MD, attending oncologist, head of Oncology and Gynecology Service, Tel Aviv Sourasky Medical Center, on research into treatments for specific types of ovarian cancer. Safra says in particular, the usage of PARP inhibitors in gynecological cancers has become  a more popular route of treatment.


Safra also touches on researching new treatments in patients with ovarian cancers that do not have a BRC mutation. She said this research currently includes trying to find patients that have a BRC-like signature, which will light the way for researchers to uncover better treatments.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.